| Peer-Reviewed

Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis

Received: 6 March 2021     Accepted: 16 March 2021     Published: 19 August 2021
Views:       Downloads:
Abstract

Introduction: Matrix metalloproteinase (MMP)-2 is a member of MMPs family which is zinc-dependent endopeptidases that degrade all components of ECM and vascular basement membrane. MMPs are closely involved in tumor invasion and metastasis. Aim of the work: is to evaluate the immune-expression and clinical significance of MMPs molecule in patients with pancreatic carcinoma. Materials and Methods: A total of 25 pancreatic carcinomas were evaluated for expression of MMP-2 by immunohistochemical technique. The expression was evaluated. The study included 24/25 cases of PDAC and 1/25 acinar cell carcinoma. PDAC included 5/24 cases of well differentiated, 16/24 cases of moderately differentiated, 3/24 cases of poorly differentiated adenocarcinoma. Results: Pancreatic carcinoma specimens showed positive cytoplasmic MMP-2 staining with high expression in 88% of studied specimens as their IRS ranged from 6/9 to 9/9 with high extent and intensity. There was a statistically significant relationship between MMP-2 expression and high grade in PDAC (p<0.024). Conclusion: MMP-2 was expressed in PDAC and not in pancreatitis cases. The expression of MMP-2 was correlated with high histological grade and poor prognosis in PDAC.

Published in International Journal of Immunology (Volume 9, Issue 3)
DOI 10.11648/j.iji.20210903.12
Page(s) 47-53
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

(MMP-2) Matrix Metalloproteinases, (PDAC) Pancreatic Duct Adenocarcinoma, Immunohistochemistry, ECM Extracellular Matrix

References
[1] Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. “Identification of pancreatic cancer stem cells,” Cancer Research, vol. 67, no. 3, pp. 1030–1037, 2007.
[2] Nai Q, Luo H, Zhang P, Hossain M. A, Gu P, Sidhom IW, Mathew T, Islam M, Yousif AM, Sen S. How Early Can Pancreatic Cancer Be Recognized? a case report and review of literature: Cancer statistics. Cancer J Clin 2014; 64: 9-29.
[3] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424.
[4] Mostafa ME, Erbarut-Seven I, Pehlivanoglu B, Adsay V. Pathologic classification of pancreatic cancers. Chin Clin Oncol 2017; 6: 59.
[5] SEER Cancer Statistics Review, 1975-2013. National Cancer Institute, Bethesda, MD. 2016.
[6] Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA Cancer J. Clin., https://doi.org/10.3322/caac.21551
[7] Binker MG, Binker-Cosen MJ, Binker-Cosen AA, Cosen-Binker LI. Microenvironmental factors and extracellular matrix degradation in pancreatic cancer. JOP 2014; 15: 280-285.
[8] Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605–1617.
[9] Bijlsma MF and Van Laarhoven HWM. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: A systematic review and critical appraisal. Cancer Metastasis Rev. 2015, 34, 97–114.
[10] Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395–406.
[11] Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer—Roles in threat and therapy. Asian Pac. J. Cancer Prev. 2014, 15, 1085–1091.
[12] Radisky E. S, Raeeszadeh-Sarmazdeh M, Radisky D. C. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J. Cell Biochem. 2017, 118, 3531–3548.
[13] Roy, R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M and Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014; 111: 1772-1779.
[14] Zhai LL, Cai1 CY, Wu Y, Tang ZG. Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma, Int J Clin Exp Pathol 2015; 8: 682-691.
[15] Gonzalez RS. WHO classification. Pathology Outlines.com website. https://www.pathologyoutlines.com/topic/pancreaswho.html. Accessed February 2nd, 2021.
[16] Dragovich T. Pancreatic cancer staging 2020, Oncology.
[17] American Cancer Society's (ACS) publication, Cancer Facts & Figures 2020, and the ACS website (January 2020).
[18] Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N and Peros G. The Expression of Matrix Metalloproteinases-2 and -9 and their Tissue Inhibitor 2 in Pancreatic Ductal and Ampullary Carcinoma and their Relation to Angiogenesis and Clinico-pathological Parameters. Anticancer research, 2008; 28: 1875-1882.
[19] Jakubowska K, Pryczynicz A, Januszewska J, Sidorkiewicz I, Andrzej Kemona A, Niewiński A, Lewczuk L, Kędra B, and Guzińska-Ustymowicz K. Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Hindawi Publishing Corporation, Disease Markers 2016; 1-7.
[20] Slapak EJ, Duitman JW, Tekin C, Bijlsma MF and Spek CA. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Biology 2020, (9), 80.
[21] Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immuno-reactive protein as a prognostic marker in bladder cancer. Urology 2003; 62: 952-957.
[22] Yao Z, Yuan T, Wang H, Yao S, Zhao Y, Liu Y, Jin S, Chu J, Xu Y, Zhou W, Yang S, Liu Y. MMP-2 together with MMP-9 overexpression correlated with lymph node metastasis and poor prognosis in early gastric carcinoma Tumour Biol. 2017 Jun; 39 (6): 1010428317700411.
[23] Wu ZY, Li JH, Zhan WH and He YL. Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol 2006; 12: 2941-2944.
[24] Dragutinović VV, Radonjić NV, Petronijević ND, Tatić SB, Dimitrijević IB, Radovanović NS, Zoran V Krivokapić ZV. Matrix metalloproteinase-2 and (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Mol Cell Biochem 2011; 355: 173-178.
[25] Aparna M, Rao L, Kunhikatta V, Radhakrishnan R. The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma. J Oral Pathol Med 2014.
[26] Choi EK, Kim MH, Jang SJ, Lee KH, Hwang CY, Moon SH, Lee TY, Koh CO, Park DH, Lee SS, Seo DW, Lee SK. Differences in pancreatic immunohistochemical staining profiles of TGF-beta1, MMP-2, and TIMP-2 between autoimmune and alcoholic chronic pancreatitis. Pancreas: October 2009 - Volume 38: (7): 739-745.
[27] Manjari KS, Nallari P, Venkateshwari A. Matrix metalloproteinases in pancreatitis: current insights. Metalloproteinases In Medicine, January 2017 Volume (4): 15-23.
Cite This Article
  • APA Style

    Afaf Taha El-Nashar, Eman Muhammad Salah Muhammad, Mohammed Hamdy Sayed, Said Abuel-kheer Mohammed. (2021). Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis. International Journal of Immunology, 9(3), 47-53. https://doi.org/10.11648/j.iji.20210903.12

    Copy | Download

    ACS Style

    Afaf Taha El-Nashar; Eman Muhammad Salah Muhammad; Mohammed Hamdy Sayed; Said Abuel-kheer Mohammed. Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis. Int. J. Immunol. 2021, 9(3), 47-53. doi: 10.11648/j.iji.20210903.12

    Copy | Download

    AMA Style

    Afaf Taha El-Nashar, Eman Muhammad Salah Muhammad, Mohammed Hamdy Sayed, Said Abuel-kheer Mohammed. Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis. Int J Immunol. 2021;9(3):47-53. doi: 10.11648/j.iji.20210903.12

    Copy | Download

  • @article{10.11648/j.iji.20210903.12,
      author = {Afaf Taha El-Nashar and Eman Muhammad Salah Muhammad and Mohammed Hamdy Sayed and Said Abuel-kheer Mohammed},
      title = {Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis},
      journal = {International Journal of Immunology},
      volume = {9},
      number = {3},
      pages = {47-53},
      doi = {10.11648/j.iji.20210903.12},
      url = {https://doi.org/10.11648/j.iji.20210903.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20210903.12},
      abstract = {Introduction: Matrix metalloproteinase (MMP)-2 is a member of MMPs family which is zinc-dependent endopeptidases that degrade all components of ECM and vascular basement membrane. MMPs are closely involved in tumor invasion and metastasis. Aim of the work: is to evaluate the immune-expression and clinical significance of MMPs molecule in patients with pancreatic carcinoma. Materials and Methods: A total of 25 pancreatic carcinomas were evaluated for expression of MMP-2 by immunohistochemical technique. The expression was evaluated. The study included 24/25 cases of PDAC and 1/25 acinar cell carcinoma. PDAC included 5/24 cases of well differentiated, 16/24 cases of moderately differentiated, 3/24 cases of poorly differentiated adenocarcinoma. Results: Pancreatic carcinoma specimens showed positive cytoplasmic MMP-2 staining with high expression in 88% of studied specimens as their IRS ranged from 6/9 to 9/9 with high extent and intensity. There was a statistically significant relationship between MMP-2 expression and high grade in PDAC (pConclusion: MMP-2 was expressed in PDAC and not in pancreatitis cases. The expression of MMP-2 was correlated with high histological grade and poor prognosis in PDAC.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis
    AU  - Afaf Taha El-Nashar
    AU  - Eman Muhammad Salah Muhammad
    AU  - Mohammed Hamdy Sayed
    AU  - Said Abuel-kheer Mohammed
    Y1  - 2021/08/19
    PY  - 2021
    N1  - https://doi.org/10.11648/j.iji.20210903.12
    DO  - 10.11648/j.iji.20210903.12
    T2  - International Journal of Immunology
    JF  - International Journal of Immunology
    JO  - International Journal of Immunology
    SP  - 47
    EP  - 53
    PB  - Science Publishing Group
    SN  - 2329-1753
    UR  - https://doi.org/10.11648/j.iji.20210903.12
    AB  - Introduction: Matrix metalloproteinase (MMP)-2 is a member of MMPs family which is zinc-dependent endopeptidases that degrade all components of ECM and vascular basement membrane. MMPs are closely involved in tumor invasion and metastasis. Aim of the work: is to evaluate the immune-expression and clinical significance of MMPs molecule in patients with pancreatic carcinoma. Materials and Methods: A total of 25 pancreatic carcinomas were evaluated for expression of MMP-2 by immunohistochemical technique. The expression was evaluated. The study included 24/25 cases of PDAC and 1/25 acinar cell carcinoma. PDAC included 5/24 cases of well differentiated, 16/24 cases of moderately differentiated, 3/24 cases of poorly differentiated adenocarcinoma. Results: Pancreatic carcinoma specimens showed positive cytoplasmic MMP-2 staining with high expression in 88% of studied specimens as their IRS ranged from 6/9 to 9/9 with high extent and intensity. There was a statistically significant relationship between MMP-2 expression and high grade in PDAC (pConclusion: MMP-2 was expressed in PDAC and not in pancreatitis cases. The expression of MMP-2 was correlated with high histological grade and poor prognosis in PDAC.
    VL  - 9
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Pathology, Sohag University, Sohag, Egypt

  • Department of Pathology, Sohag University, Sohag, Egypt

  • Department of Pathology, El-Azhar University, Assiut, Egypt

  • Department of Pathology, El-Azhar University, Assiut, Egypt

  • Sections